Identification of CHI3L1 and MASP2 as a biomarker pair for liver cancer through integrative secretome and transcriptome analysis

Proteomics - Clinical Applications

Volumn 3, Issue 5, 2009, Pages 541-551

  Wang, Jun ^a   Gao, Feng ^a   Mo, Fan ^a   Hong, Xu ^a   Wang, Hongyang ^b   Zheng, Shusen ^a   Lin, Biaoyang ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b SEMICONDUCTOR MANUFACTURING INTERNATIONAL CORPORATION   (China)

Author keywords

Biomarker; Chitinase 3 like protein 1; Hepatocellular carcinoma; Secretome

Indexed keywords

BIOLOGICAL MARKER; CHITINASE; CHITINASE 3 LIKE PROTEIN 1; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 2; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; TANDEM MASS SPECTROMETRY; TRANSCRIPTOMICS; UPREGULATION;

EID: 67649424354     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800145     Document Type: Article

References (43)

1. Parkin, D. M., Bray, F., Ferlay, J., Pisani, P., Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001, 94, 153-156.
2. Spangenberg, H. C., Thimme, R., Blum, H. E., Serum markers of hepatocellular carcinoma. Semin. Liver Dis. 2006, 26, 385-390.
3. Fujiyama, S., Tanaka, M., Maeda, S., Ashihara, H. et al., Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002, 62 Suppl. 1, 57-63.
4. Li, C., Tan, Y. X., Zhou, H., Ding, S. J. et al., Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: Identification of potential tumor markers. Proteomics 2005, 5, 1125-1139.
5. Tu, D. G., Wang, S. T., Chang, T. T., Chiu, N. T., Yao, W. J., The value of serum tissue polypeptide specific antigen in the diagnosis of hepatocellular carcinoma. Cancer 1999, 85, 1039-1043.
6. Buscarini, L., Sbolli, G., Cavanna, L., Civardi, G. et al., Clinical and diagnostic features of 67 cases of hepatocellular carcinoma. Oncology 1987, 44, 93-97.
7. Anderson, L., Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563, 23-60.
8. Nesvizhskii, A. I., Keller, A., Kolker, E., Aebersold, R., A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75, 4646-4658.
9. Zeeberg, B. R., Feng, W., Wang, G., Wang, M. D. et al., GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol. 2003, 4, R28.
10. Liu, H., Sadygov, R. G., Yates, J. R., 3rd, A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 2004, 76, 4193-4201.
11. Lin, B., White, J. T., Lu, W., Xie, T. et al., Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res. 2005, 65, 3081-3091.
12. Chen, X., Cheung, S. T., So, S., Fan, S. T. et al., Gene expression patterns in human liver cancers. Mol. Biol. Cell 2002, 13, 1929-1939.
13. Lee, J. S., Chu, I. S., Heo, J., Calvisi, D. F. et al., Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (Baltimore), Md 2004, 40, 667-676.
14. Lee, J. S., Thorgeirsson, S. S., Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004, 127, S51-55.
15. Rehli, M., Krause, S. W., Andreesen, R., Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997, 43, 221-225.
16. Bleau, G., Massicotte, F., Merlen, Y., Boisvert, C., Mammalian chitinase-like proteins. Exs 1999, 87, 211-221.
17. Hormigo, A., Gu, B., Karimi, S., Riedel, E. et al., YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer Res. 2006, 12, 5698-5704.
18. Diefenbach, C. S., Shah, Z., Iasonos, A., Barakat, R. R. et al., Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol. Oncol. 2007, 104, 435-442.
19. Dupont, J., Tanwar, M. K., Thaler, H. T., Fleisher, M. et al., Early detection and prognosis of ovarian cancer using serum YKL-40. J. Clin. Oncol. 2004, 22, 3330-3339.
20. Hood, L., Heath, J. R., Phelps, M. E., Lin, B., Systems biology and new technologies enable predictive and preventative medicine. Science 2004, 306, 640-643.
21. Thiel, S., Vorup-Jensen, T., Stover, C. M., Schwaeble, W. et al., A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997, 386, 506-510.
22. Celis, J. E., Gromov, P., Cabezon, T., Moreira, J. M. et al., Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics 2004, 3, 327-344.
23. Kulasingam, V., Diamandis, E. P., Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol. Cell. Proteomics 2007, 6, 1997-2011.
24. Martin, D. B., Gifford, D. R., Wright, M. E., Keller, A. et al., Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res. 2004, 64, 347-355.
25. Zybailov, B., Coleman, M. K., Florens, L., Washburn, M. P., Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. Anal. Chem. 2005, 77, 6218-6224.
26. Sun, W., Xing, B., Sun, Y., Du, X. et al., Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol. Cell. Proteomics 2007.
27. Li, C., Hong, Y., Tan, Y. X., Zhou, H. et al., Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capturemicrodissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol. Cell. Proteomics 2004, 3, 399-409.
28. Fujii, K., Kondo, T., Yokoo, H., Yamada, T. et al., Proteomic study of human hepatocellular carcinoma using twodimensional difference gel electrophoresis with saturation cysteine dye. Proteomics 2005, 5, 1411-1422.
29. Blanc, J. F., Lalanne, C., Plomion, C., Schmitter, J. M. et al., Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics 2005, 5, 3778-3789.
30. Hu, T. H., Huang, C. C., Liu, L. F., Lin, P. R. et al., Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 2003, 98, 1444-1456.
31. Kishima, Y., Yoshida, K., Enomoto, H., Yamamoto, M. et al., Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells. Hepato-Gastroenterol. 2002, 49, 1639-1644.
32. Sakai, M., Muramatsu, M., Regulation of glutathione transferase P: a tumormarker of hepatocarcinogenesis. Biochem. Biophys. Res. Commun. 2007, 357, 575-578.
33. Takekoshi, H., Mizoguchi, T., Komasa, Y., Chubachi, H. et al., Suppression of glutathione S-transferase placental form-positive foci development in rat hepatocarcinogenesis by Chlorella pyrenoidosa. Oncol. Reports 2005, 14, 409-414.
34. Zhou, T., Evans, A. A., London, W. T., Xia, X. et al., Glutathione S-transferase expression in hepatitis B virus-associated human hepatocellular carcinogenesis. Cancer Res. 1997, 57, 2749-2753.
35. Castaldo, G., Calcagno, G., Sibillo, R., Cuomo, R. et al., Quantitative analysis of aldolase A mRNA in liver discriminates between hepatocellular carcinoma and cirrhosis. Clin. Chem. 2000, 46, 901-906.
36. Zeindl-Eberhart, E., Jungblut, P., Rabes, H.M., Expression of tumor-associated protein variants in chemically induced rat hepatomas and transformed rat liver cell lines determined by two-dimensional electrophoresis. Electrophoresis 1994, 15, 372-381.
37. Chignard, N., Shang, S., Wang, H., Marrero, J. et al., Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera. Gastroenterology 2006, 130, 2010-2022.
38. Cintin, C., Johansen, J. S., Christensen, I. J., Price, P. A. et al., Serum YKL-40 and colorectal cancer. Brit. J. Cancer 1999, 79, 1494-1499.
39. Johansen, J. S., Cintin, C., Jorgensen, M., Kamby, C., Price, P. A., Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur. J. Cancer 1995, 31A, 1437-1442.
40. Johansen, J. S., Christoffersen, P., Moller, S., Price, P. A. et al., Serum YKL-40 is increased in patients with hepatic fibrosis. J. Hepatol. 2000, 32, 911-920.
41. Kamal, S. M., Turner, B., He, Q., Rasenack, J. et al., Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology (Baltimore), Md 2006, 43, 771-779.
42. Fontana, R. J., Goodman, Z. D., Dienstag, J. L., Bonkovsky, H. L. et al., Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (Baltimore), Md 2008, 47, 789-798.
43. Alcolado, R., Arthur, M. J., Iredale, J. P., Pathogenesis of liver fibrosis. Clin. Sci. (Lond) 1997, 92, 103-112.